{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:08:56Z","timestamp":1785848936118,"version":"3.56.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AI074492"],"award-info":[{"award-number":["T32AI074492"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hepatitis A virus (HAV) infection is a serious health concern among people with human immunodeficiency virus (HIV). Coinfection with HAV and HIV is linked to increased hepatitis A viral load, elevated HIV RNA, and potential disruption of HIV treatment caused by liver dysfunction. Three vaccines for the prevention of HAV are currently approved for usage in the United States: 2 monovalent inactivated vaccines (hepatitis A vaccine, inactivated [GSK] and hepatitis A vaccine, inactivated [Merck]) and 1 hepatitis A (inactivated) and hepatitis B (recombinant) vaccine (GSK). Among people with HIV (PWH), seroconversion rates and antibody titers to HAV vaccines tend to be lower and less persistent than in immunocompetent individuals, with a notable difference among PWH with a lower CD4 cell count. We highlight in this review the potential need for serologic monitoring and revaccination strategies that would optimize lifelong protection against HAV in PWH.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf143","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:45:01Z","timestamp":1744364701000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Durability of Immune Response After Receipt of Hepatitis A Vaccine in People With Human Immunodeficiency Virus"],"prefix":"10.1093","volume":"12","author":[{"given":"Bahaa","family":"Kazzi","sequence":"first","affiliation":[{"name":"The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Naji","sequence":"additional","affiliation":[{"name":"The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8722-3833","authenticated-orcid":false,"given":"Serena Maria","family":"Dib","sequence":"additional","affiliation":[{"name":"The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Khalil","sequence":"additional","affiliation":[{"name":"The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8248-4074","authenticated-orcid":false,"given":"Sonia","family":"Tandon Wimalasana","sequence":"additional","affiliation":[{"name":"The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1495-7544","authenticated-orcid":false,"given":"Diane","family":"Saint-Victor","sequence":"additional","affiliation":[{"name":"Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ighovwerha","family":"Ofotokun","sequence":"additional","affiliation":[{"name":"The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-7919","authenticated-orcid":false,"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[{"name":"The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University , Decatur, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2025052712082944700_ofaf143-B1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0972-5229.148636","article-title":"Recent advances in management of acute liver failure","volume":"19","author":"Panackel","year":"2015","journal-title":"Indian J Crit Care Med"},{"key":"2025052712082944700_ofaf143-B2","author":"World Health Organization. Hepatitis A vaccines: WHO position paper, October 2022"},{"key":"2025052712082944700_ofaf143-B3","author":"2022 Viral Hepatitis Surveillance Report. Centers for Disease Control and Prevention (CDC)","year":"2024"},{"key":"2025052712082944700_ofaf143-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6905a1","article-title":"Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020","volume":"69","author":"Nelson","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2025052712082944700_ofaf143-B5","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.ijid.2008.12.009","article-title":"Seroprevalence of hepatitis A virus infection in persons with HIV infection in Taiwan: implications for hepatitis A vaccination","volume":"13","author":"Sun","year":"2009","journal-title":"Int J Infect Dis"},{"key":"2025052712082944700_ofaf143-B6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/338152","article-title":"Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection","volume":"34","author":"Ida","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2025052712082944700_ofaf143-B7","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/cid\/ciy328","article-title":"Less severe but prolonged course of acute hepatitis A in human immunodeficiency virus (HIV)\u2013infected patients compared with HIV-uninfected patients during an outbreak: a multicenter observational study","volume":"67","author":"Lee","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025052712082944700_ofaf143-B8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1545109710385692","article-title":"Impact of acute hepatitis A virus (HAV) infection on HIV viral load in HIV-infected patients and influence of HIV infection on acute HAV infection","volume":"10","author":"Gallego","year":"2011","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"2025052712082944700_ofaf143-B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jmv.10163","article-title":"Prolonged hepatitis A infection in an HIV-1 seropositive patient","volume":"68","author":"Costa-Mattioli","year":"2002","journal-title":"J Med Virol"},{"key":"2025052712082944700_ofaf143-B10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1086\/318478","article-title":"Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus","volume":"32","author":"Fonquernie","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2025052712082944700_ofaf143-B11","author":"US Food and Drug Administration","year":"2020"},{"key":"2025052712082944700_ofaf143-B12","author":"US Food and Drug Administration","year":"2023"},{"key":"2025052712082944700_ofaf143-B13","article-title":"Prescribing information [package insert]. TWINRIX (hepatitis A & hepatitis B [recombinant] vaccine)","author":"US Food and Drug Administration","year":"2023"},{"key":"2025052712082944700_ofaf143-B14","author":"EACS Guidelines (V12.0)","year":"2023"},{"key":"2025052712082944700_ofaf143-B15","author":"Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association and Infectious Diseases Society of America","year":"2024"},{"key":"2025052712082944700_ofaf143-B16","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/hiv.12424","article-title":"British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med"},{"key":"2025052712082944700_ofaf143-B17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.1994.03510410040030","article-title":"Protection against hepatitis A by an inactivated vaccine","volume":"271","author":"Innis","year":"1994","journal-title":"JAMA"},{"key":"2025052712082944700_ofaf143-B18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199208133270702","article-title":"A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children","volume":"327","author":"Werzberger","year":"1992","journal-title":"N Engl J Med"},{"key":"2025052712082944700_ofaf143-B19","first-page":"4710","article-title":"A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults","volume":"19","author":"Joines","year":"2001","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/liv.13468","article-title":"Incidence of acute hepatitis A among HIV-positive patients during an outbreak among MSM in Taiwan: impact of HAV vaccination","volume":"38","author":"Chen","year":"2018","journal-title":"Liver Int"},{"key":"2025052712082944700_ofaf143-B21","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/cid\/ciz471","article-title":"Effect of a hepatitis A vaccination campaign during a hepatitis A outbreak in Taiwan, 2015\u20132017: a modeling study","volume":"70","author":"Lin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025052712082944700_ofaf143-B22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.29780","article-title":"Serologic responses and effectiveness of hepatitis A vaccination among human immunodeficiency virus\u2013positive individuals during the outbreak of acute hepatitis A","volume":"68","author":"Lin","year":"2018","journal-title":"Hepatology"},{"key":"2025052712082944700_ofaf143-B23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1086\/424666","article-title":"Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects","volume":"39","author":"Wallace","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2025052712082944700_ofaf143-B24","first-page":"272","article-title":"Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis","volume":"24","author":"Shire","year":"2006","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B25","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"58","author":"Kerneis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025052712082944700_ofaf143-B26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/INF.0b013e31816454a3","article-title":"Antibody response to hepatitis A immunization among human immunodeficiency virus\u2013infected children and adolescents","volume":"27","author":"Siberry","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2025052712082944700_ofaf143-B27","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/QAI.0b013e31821fdec3","article-title":"Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults","volume":"57","author":"Kerneis","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052712082944700_ofaf143-B28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/infdis\/jiy224","article-title":"Comparable serologic responses to 2 different combinations of inactivated hepatitis A virus vaccines in HIV-positive patients during an acute hepatitis A outbreak in Taiwan","volume":"218","author":"Lin","year":"2018","journal-title":"J Infect Dis"},{"key":"2025052712082944700_ofaf143-B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cimid.2017.07.006","article-title":"Predictors of humoral response to recommended vaccines in HIV-infected adults","volume":"54","author":"Tsachouridou","year":"2017","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"2025052712082944700_ofaf143-B30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/498979","article-title":"Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy","volume":"193","author":"Weinberg","year":"2006","journal-title":"J Infect Dis"},{"key":"2025052712082944700_ofaf143-B31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QAI.0b013e318183a9c0","article-title":"Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study","volume":"49","author":"Launay","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052712082944700_ofaf143-B32","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/hep.26210","article-title":"Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus\u2013infected and \u2013uninfected men who have sex with men","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"2025052712082944700_ofaf143-B33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0000000000001990","article-title":"Brief report: response to hepatitis A virus vaccine in HIV-infected patients within a retrospective, multicentric cohort: facing hepatitis A outbreaks in the clinical practice","volume":"81","author":"Neukam","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025052712082944700_ofaf143-B34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.medmal.2020.09.016","article-title":"Low immune response rate of HIV-infected patients to a single injection of hepatitis A vaccine","volume":"51","author":"Noel","year":"2021","journal-title":"Infect Dis Now"},{"key":"2025052712082944700_ofaf143-B35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jmii.2020.06.014","article-title":"Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: is one dose enough?","volume":"55","author":"Tsai","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"2025052712082944700_ofaf143-B36","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1086\/516512","article-title":"Response to hepatitis A vaccination in human immunodeficiency virus\u2013infected and \u2013uninfected homosexual men","volume":"176","author":"Neilsen","year":"1997","journal-title":"J Infect Dis"},{"key":"2025052712082944700_ofaf143-B37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jmv.1890460109","article-title":"Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men","volume":"46","author":"Hess","year":"1995","journal-title":"J Med Virol"},{"key":"2025052712082944700_ofaf143-B38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/374562","article-title":"Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus\u2013infected patients: a double-blind, randomized, placebo-controlled trial","volume":"187","author":"Kemper","year":"2003","journal-title":"J Infect Dis"},{"key":"2025052712082944700_ofaf143-B39","first-page":"606","article-title":"Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in human immunodeficiency virus\u2013positive adults on antiretroviral therapy","volume":"215","author":"Cheng","year":"2017","journal-title":"J Infect Dis"},{"key":"2025052712082944700_ofaf143-B40","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1086\/593335","article-title":"Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults","volume":"198","author":"Hammitt","year":"2008","journal-title":"J Infect Dis"},{"key":"2025052712082944700_ofaf143-B41","first-page":"2278","article-title":"Immune response to hepatitis A vaccine in patients with HIV","volume":"37","author":"Fritzsche","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B42","first-page":"1328","article-title":"Hepatitis A vaccine response in HIV-infected patients: are TWINRIX and HAVRIX interchangeable?","volume":"31","author":"Jimenez","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1258\/ijsa.2011.011297","article-title":"Immune response to hepatitis A vaccination in HIV-infected men in Greece","volume":"23","author":"Kourkounti","year":"2012","journal-title":"Int J STD AIDS"},{"key":"2025052712082944700_ofaf143-B44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2893.2005.00658.x","article-title":"Response to hepatitis A vaccine in HIV-positive patients","volume":"13","author":"Weissman","year":"2006","journal-title":"J Viral Hepat"},{"key":"2025052712082944700_ofaf143-B45","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1128\/CVI.00264-12","article-title":"Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus\u2013infected children living in Switzerland","volume":"19","author":"Crisinel","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"2025052712082944700_ofaf143-B46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/vim.2012.0100","article-title":"Hepatitis A vaccination and immunological parameters in HIV-infected patients","volume":"26","author":"Kourkounti","year":"2013","journal-title":"Viral Immunol"},{"key":"2025052712082944700_ofaf143-B47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/0956462413518902","article-title":"Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation","volume":"25","author":"Jablonowska","year":"2014","journal-title":"Int J STD AIDS"},{"key":"2025052712082944700_ofaf143-B48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2893.2006.00822.x","article-title":"Predictors of immunity after hepatitis A vaccination in HIV-infected persons","volume":"14","author":"Overton","year":"2007","journal-title":"J Viral Hepat"},{"key":"2025052712082944700_ofaf143-B49","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/infdis\/jir180","article-title":"Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults","volume":"203","author":"Crum-Cianflone","year":"2011","journal-title":"J Infect Dis"},{"key":"2025052712082944700_ofaf143-B50","first-page":"3668","article-title":"Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy","volume":"31","author":"Mena","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/hep.30495","article-title":"Early seroreversion after 2 doses of hepatitis A vaccination in human immunodeficiency virus\u2013positive patients: incidence and associated factors","volume":"70","author":"Huang","year":"2019","journal-title":"Hepatology"},{"key":"2025052712082944700_ofaf143-B52","first-page":"3","article-title":"Long-term protective effects of hepatitis A vaccines. A systematic review","volume":"31","author":"Ott","year":"2012","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B53","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1080\/21645515.2020.1819742","article-title":"Hepatitis A vaccination and its immunological and epidemiological long-term effects\u2014a review of the evidence","volume":"17","author":"Herzog","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2025052712082944700_ofaf143-B54","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/infdis\/jis710","article-title":"Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series","volume":"207","author":"Raczniak","year":"2013","journal-title":"J Infect Dis"},{"key":"2025052712082944700_ofaf143-B55","first-page":"5723","article-title":"Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions","volume":"33","author":"Theeten","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B56","first-page":"1507","article-title":"Model based estimates of long-term persistence of inactivated hepatitis A vaccine\u2013induced antibodies in adults","volume":"32","author":"Hens","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1096-9071(200101)63:1<1::AID-JMV1000>3.0.CO;2-U","article-title":"Inactivated hepatitis A vaccine\u2013induced antibodies: follow-up and estimates of long-term persistence","volume":"63","author":"Van Herck","year":"2001","journal-title":"J Med Virol"},{"key":"2025052712082944700_ofaf143-B58","doi-asserted-by":"crossref","first-page":"2239946","DOI":"10.1080\/22221751.2023.2239946","article-title":"Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study","volume":"12","author":"Lin","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"2025052712082944700_ofaf143-B59","first-page":"176","article-title":"Antibody persistence 7 years after hepatitis-A vaccine in children with human immunodeficiency virus infection","volume":"81","author":"V\u00e1zquez-Rosales","year":"2024","journal-title":"Bol Med Hosp Infant Mex"},{"key":"2025052712082944700_ofaf143-B60","first-page":"142","article-title":"Persistence of hepatitis A virus antibodies after primary immunization and response to revaccination in children and adolescents with perinatal HIV exposure [in Portuguese]","volume":"33","author":"Gouv\u00eaa Ade","year":"2015","journal-title":"Rev Paul Pediatr"},{"key":"2025052712082944700_ofaf143-B61","first-page":"3813","article-title":"A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection","volume":"33","author":"Melgaco","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"2025052712082944700_ofaf143-B62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/jmv.10574","article-title":"Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course","volume":"72","author":"Van Herck","year":"2004","journal-title":"J Med Virol"},{"key":"2025052712082944700_ofaf143-B63","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.13665","article-title":"Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination","volume":"38","author":"Chen","year":"2018","journal-title":"Liver Int"},{"key":"2025052712082944700_ofaf143-B64","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/cid\/ciad206","article-title":"A randomized clinical trial of 1-dose vs accelerated 2-dose schedule for hepatitis A virus (HAV) revaccination among people with human immunodeficiency virus who were nonresponders or had seroreversion after primary HAV vaccination","volume":"77","author":"Chen","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025052712082944700_ofaf143-B65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","article-title":"Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population","volume":"31","author":"Gueler","year":"2017","journal-title":"AIDS"},{"key":"2025052712082944700_ofaf143-B66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/0003-4819-155-4-201108160-00358","article-title":"Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda","volume":"155","author":"Mills","year":"2011","journal-title":"Ann Intern Med"},{"key":"2025052712082944700_ofaf143-B67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","article-title":"Life expectancy living with HIV: recent estimates and future implications","volume":"26","author":"Nakagawa","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2025052712082944700_ofaf143-B68","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/QAD.0b013e32833a3946","article-title":". Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals","volume":"24","author":"van Sighem","year":"2010","journal-title":"AIDS"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf143\/62911634\/ofaf143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf143\/62911634\/ofaf143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:09:21Z","timestamp":1748362161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf143\/8111003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf143","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,27]]},"article-number":"ofaf143"}}